

1           **Multiple Cross Displacement Amplification Coupled with Gold**  
2           **Nanoparticles-Based Lateral Flow Biosensor for Detection of**  
3           **the Mobilized Colistin Resistance Gene *mcr-1***

4  
5   **Lin Gong,<sup>a</sup> Ernan Liu,<sup>a</sup> Jie Che,<sup>b</sup> Juan Li,<sup>b</sup> Xiaoli Liu,<sup>a</sup> Huiqiong Xu,<sup>a</sup>**

6   **Jiansheng Liang<sup>a#</sup>**

7  
8   <sup>a</sup>Department of Disinfection and Pest Control, Wuhan Centers for Disease Prevention &  
9   Control, Wuhan, Hubei, China

10   <sup>b</sup>State Key Laboratory for Infectious Disease Prevention and Control, Collaborative  
11   Innovation Center for Diagnosis and Treatment of Infectious Disease, National Institute for  
12   Communicable Disease Control and Prevention, China CDC, Beijing, China

13  
14  
15   **#Corresponding author:** Jiansheng Liang

16   Mailing address: Wuhan Centers for Disease Prevention & Control, Wuhan, Hubei, China.

17   Phone +86-27-8580-1825, Fax +86-27-8580-5111, E-mail: wh-ljs@sohu.com.

18  
19   **Running title: Detection of *mcr-1* by MCDA-LFB assay**

20   **Keywords:** *mcr-1*, colistin resistance, MCDA-LFB, detection assay

21

22 **Abstract**

23 Fast dissemination of the mobilized colistin resistance (*mcr*) gene *mcr-1* in  
24 *Enterobacteriaceae* causes a huge threat to the treatment of severe infection. In the current  
25 report, a multiple cross displacement amplification (MCDA) coupled with the detection of  
26 amplified products by gold nanoparticles-based lateral flow biosensor (LFB) assay  
27 (MCDA-LFB) was established to identify the *mcr-1* gene with simpleness, rapidity,  
28 specificity and sensitivity. The MCDA-LFB assay was performed at a isothermal temperature  
29 (63°C) for only 30 min during the amplification stage, and the reaction products were directly  
30 identified by using LFB which obtained the result with 2 min. The entire process of  
31 experiments, from templates extraction to result judging, was accomplished less than 60 min.  
32 For the analytical specificity of this method, all of the 16 *mcr-1*-producing strains were  
33 positive, and all of the non-*mcr-1* isolates got the negative results. The sensitivity of  
34 *mcr-1*-MCDA-LFB assay was as little as 600 fg of plasmid DNA per reaction in pure culture,  
35 and approximately  $4.5 \times 10^3$  CFU/mL ( $\sim 4.5$  CFU/reaction) in fecal samples spiked with 100  
36  $\mu$ l of strains. Therefore, this technique established in the present study is suitable for the  
37 surveillance of *mcr-1* gene in clinic and livestock industry.

38

## 39 **Introduction**

40 The rapid increase of carbapenem-resistant Enterobacteriaceae (CRE) expressing  
41 *Klebsiella pneumoniae* carbapenemase(KPC), New Delhi metallo-betaactamase(NDM) and  
42 oxacillinase(OXA) OXA-48 has risen serious concerns in clinic. Colistin, a ‘last resort’  
43 antibiotic, has a crucial role for treating the infection caused by those species (1).  
44 Therefore, that the number of colistin consumptions are increasing along with the global  
45 augment of CRE bring about the risk of emerging resistance (2).

46 Resistance to colistin was linked with chromosomal resistance mechanisms in  
47 varieties of strains in the past (3). Since a new mobilized colistin resistance gene, *mcr-1*,  
48 carried by plasmid in an *Escherichia coli* was first reported in China in 2015 (4), which  
49 has been identified in numerous countries. China, Germany and Vietnam carry an  
50 important proportion of positive samples (5). The *mcr-1*-positive bacterial species include  
51 *Salmonella enterica*, *Escherichia coli*, *Escherichia fergusonii*, *Enterobacter aerogenes*,  
52 *Klebsiella pneumoniae*, *Citrobacter braaki* and *Klebsiella aerogenes* (5-11). Besides  
53 discovered in Clinical samples, *mcr-1* is also detected from environmental settings: meat  
54 and vegetable products purchased from markets, Animal feces collected from farms, fecal  
55 samples of pets gathered from pet hospital, river water and seawater (12). The wide  
56 dissemination of *mcr-1* across diversified species is benefited from many types of  
57 *mcr-1*-bearing plasmids covering IncHI2, IncI2, IncFI, IncX4 and IncX1-X2 hybrid type  
58 (13-17). Similarly, the genetic environments of *mcr-1* gene also impact its transmission. A  
59 global data set of roughly 500 isolates producing *mcr-1* analysed by whole-genome

60 sequencing (WGS) has revealed that an initial mobilized event of *mcr-1* is mediated by  
61 an ISAp11-*mcr-1-orf*-ISAp11 transposon around 2006 (5). The horizontal transfer of  
62 *mcr-1* gene causing inflation of colistin-resistant isolates will lead to the shortage of  
63 effective measures for treating infections with multidrug-resistant bacteria. Therefore, a  
64 rapid, sensitive and specific diagnostic assay for *mcr-1* detection is imperative to devise.

65 Currently, several categories of molecular diagnostic methodologies including  
66 conventional PCR and real-time PCR methods have been devised to identify *mcr-1* gene  
67 (18). Nevertheless, the requirements of highly sophisticated devices, Strictly  
68 experimental environments and well-trained professionals restrict those techniques to  
69 apply in resource-challenged areas and “on-site” detection (19). Recently, multiple cross  
70 displacement amplification (MCDA), a novel nucleic acid amplification technique, has  
71 been utilized in detection of bacterial agents, such as *Listeria monocytogenes* and  
72 methicillin-resistant *Staphylococcus aureus* (MRSA) (20, 21). With the advantages of  
73 rapidity, specificity and sensitivity, MCDA operated in a simple heater can yield  
74 amplicons from a few colonies (20, 22), the amplicons are identified by a gold  
75 nanoparticles-based lateral flow biosensor (LFB) subsequently.

76 In this study, a MCDA-LFB assay for the rapid detection of *mcr-1* was established,  
77 and the sensitivity and specificity of above method in pure culture and in spiked fecal  
78 samples were analyzed.

79

80

## 81 **Materials and Methods**

82 **Reagents and instruments.** Bacterial genomes extraction kits were obtained from  
83 Beijing ComWin Biotech Co.,Ltd.(Beijing, China). QIAGEN plasmid kits and QIAamp  
84 fast DNA stool mini kits were purchased from Qiagen Co., Ltd.(Beijing, China).  
85 Isothermal amplification kits (including reaction buffer and Bst DNA polymerase 2.0),  
86 colorimetric indicator, and disposable lateral flow biosensor were provided by  
87 BeiJing-HaiTaiZhengYuan Technology Co., Ltd.(Beijing, China). The heating thermostat  
88 (MTH-100) was purchased from Hangzhou MiU Instruments Co., Ltd.(Hangzhou, China).  
89 The UV transilluminator (UVsolo touch) was obtained from Analytik Jena(Jena,  
90 Germany). Nanodrop instrument (ND-2000) was purchased from Thermo Fisher  
91 Scientific Co., Ltd. (Massachusetts, America).

92 **Isolates and genomic template preparation.** A total of 51 organisms consisting of  
93 16 *mcr-1*-positive isolates and 35 non-*mcr-1* bacteria were used in the this study (**Table 1**).  
94 The *mcr-1*-positive bacterial species included 5 *Escherichia fergusonii*, 10 *Escherichia*  
95 *coli* and 1 *Salmonella enteritidis*. The *mcr-1*-negative isolates involved KPC-2-positive  
96 stains(*Klebsiella pneumoniae* and *Pseudomonas aeruginosa*), NDM-1-positive  
97 isolates(*Escherichia coli*, *Enterobacter cloacae* and *Klebsiella pneumoniae*),  
98 NDM-5-producing *Escherichia coli*, IMP-4-producing *Escherichia coli*, and  
99 *mcr-1*/carbapenemase-negative species (*Acinetobacter baumannii*, *Pseudomonas*  
100 *aeruginosa*, *Serratia marcescens* and *Escherichia coli*). According to the handling  
101 instruction, the genomes DNA of all strains was extracted by bacterial genomes

102 extraction kits, the plasmid DNA of *mcr-1*-producing *Escherichia fergusonii*  
103 (ICDC-ZG2016M34-3) which was acted as a representative sample for optimization of  
104 reaction condition and sensitivity detection was acquired by QIAGEN Plasmid Kits, and  
105 quantified by a Nanodrop ND-2000 instrument.

106 **Primers design of MCDA assay.** Two softwares named Primer Primer 6.0 and  
107 PrimerExplorer V4 were used to design the five pairs of MCDA primers based on *mcr-1*  
108 gene. The dimer and hairpin structures of all primers were detected by Integrated DNA  
109 Technologies design tools (23), and the specificity of which was analyzed by using Basic  
110 Local Alignment Search Tool (Blast). The relevant information of primers pairs (F1, F2,  
111 C1, C2, D1, D2, R1, R2, CP1 and CP2) about positions and sequences is displayed in **Fig.**  
112 **1** and **Table 2**. Furthermore, The FITC (Fluorescein isothiocyanate) and biotin labeled at  
113 5'end of the C1 and D1 primers, respectively, and the new primers were named as C1\*  
114 and D1\*. All of the primers were synthesized and purified by Sangon Biotechnology Co.,  
115 Ltd.(Shanghai, China) at HPLC purification grade.

116 **The standard MCDA assay.** The MCDA reaction systems were performed  
117 according to the previous studies (23). Each reaction, the total volumes of 25  $\mu$ L,  
118 included reaction buffer (12.5  $\mu$ L), Bst DNA polymerase 2.0 (1  $\mu$ L), colorimetric  
119 indicator (1  $\mu$ L), cross primers CP1 and CP2 ( 1.6  $\mu$ M each), displacement primers F1  
120 and F2 ( 0.4  $\mu$ M each ), amplification primers C1, C2, D1, D2, R1 and R2 ( 0.4  $\mu$ M each),  
121 and 1  $\mu$ L of DNA template. Mixtures including 1  $\mu$ L of DNA of NDM-1-positive  
122 *Escherichia coli* (WHCDC-WH67) and KPC-2-producing *Klebsiella pneumoniae*

123 (WHCDC-WH108) were regarded as the negative controls, and 1 $\mu$ L of distilled water  
124 contained in mixtures was served as the blank control. To assess the optimal reaction  
125 temperature of *mcr-I*-MCDA primers, the MCDA amplification systems were executed  
126 with a constant temperature in the range of 60 °C to 67°C for 40 min.

127 The MCDA reaction products were analyzed by three detection methods containing  
128 2% agarose gel electrophoresis, colorimetric indicator, and LFB (20). When employing  
129 gel electrophoresis, 3  $\mu$ L of reaction mixtures were run at 110 volts for 60 min. A ladder  
130 of multiple bands could be observed in the positive reactions, but not in the negative and  
131 blank controls. Reaction products were detected by using colorimetric indicator, the color  
132 of amplified products remained unchanged. Nevertheless, the negative and blank controls  
133 reactions changed from blue to colorless. The material, theory and operation procedure of  
134 LFB were previously described by Wang et al. (20). 0.2  $\mu$ L of amplicons followed by  
135 three drops of the running buffer consisting of 1% Tween 20 and 0.01mol/L  
136 phosphate-buffered saline were added to the well of sample pad (19). After one to two  
137 minutes, two red lines named test line (TL) and control line (CL) respectively, could be  
138 visualized in positive products, while only the CL was observed for the negative and  
139 blank control.

140 **Sensitivity and specificity of the *mcr-I*-MCDA-LFB assay.** The plasmid DNA of  
141 *Escherichia fergusonii* ICDC-ZG2016M34-3 was serially diluted (6ng, 60pg, 600fg, 60fg,  
142 and 6fg per  $\mu$ l) for sensitivity analysis of *mcr-I*-MCDA-LFB detection. The colorimetric  
143 indicator and agarose gel electrophoresis were carried out simultaneously. Each test was

144 repeated three times. The specificity of *mcr-I*-MCDA-LFB assay was evaluated with the  
145 DNA templates of 16 *mcr-I*-producing strains and 35 non-*mcr-I* strains (**Table 1**), The  
146 specificity evaluations were confirmed twice.

147 **The optimal amplification time.** In order to screen the optimal time for the  
148 *mcr-I*-MCDA-LFB assay, The MCDA mixture was completed at the reaction temperature  
149 in the range from 10 min to 40 min at 10 min intervals. Subsequently, the MCDA  
150 products were detected by LFB detection. Each amplification time was operated at two  
151 times.

152 ***Mcr-I*-MCDA-LFB detection in fecal samples.** The fecal samples were obtained  
153 from a healthy man in Wuhan, China. *Mcr-I* gene was not detected in those samples  
154 according to the microbial culture and PCR identification. The volumes of 100  $\mu$ L were  
155 taken out from the *mcr-I*-positive *Escherichia fergusonii* ICDC-ZG2016M34-3 cultures  
156 when the optical density (OD) of that reached to 0.6. The suspensions were serially  
157 diluted ( $10^{-1}$  to  $10^{-8}$ ), and the aliquots of 100  $\mu$ L dilutions ( $10^{-3}$ - $10^{-6}$ ) were incubated on  
158 nutrient agar plates with three replicates, colony forming units (CFUs) were counted  
159 subsequently. 100  $\mu$ l of diluted *mcr-I*-producing cultures ( $10^{-2}$  to  $10^{-7}$ ) with known  
160 amounts ( $4.5 \times 10^6$  to  $4.5 \times 10^1$  CFU/ mL) was respectively added to 0.2g of fecal sample  
161 and mixed well, DNA templates were extracted with the manufacturer's protocol by using  
162 QIAamp fast DNA stool mini kits. The extracted genomic DNA was dissolved in 100 $\mu$ l  
163 of elution buffer, and 1  $\mu$ l of which was used for MCDA-LFB detection as templates. A  
164 non-spiked feces sample was tested as negative control. The products of MCDA were



165 also detected by colorimetric indicator and 2% agarose gel electrophoresis. The  
166 evaluation assay for limit of detection in fecal samples was conducted triplicate.

167

## 168 **Result**

169 **The verification of *mcr-1* MCDA Products.** The *mcr-1* MCDA assays were performed  
170 at a constant temperature (63 °C) for 40 min to verify the availability of MCDA primers.  
171 Positive reaction appeared with DNA from *mcr-1*-producing *Escherichia fergusonii*  
172 (ICDC-ZG2016M34-3), but not with NDM-1-positive *Escherichia coli*  
173 (WHCDC-WH67), KPC-2-producing *Klebsiella pneumoniae* (WHCDC-WH108) and the  
174 blank control (**Fig. 2**). Therefore, the primers of *mcr-1*-MCDA was suitable for  
175 establishment of the MCDA-LFB assay to detect *mcr-1* gene.

176 **Temperature optimization for *mcr-1*-MCDA-LFB assay.** To optimize the reaction  
177 temperature of MCDA-LFB assay during the amplification stage, the plasmid DNA of  
178 *Escherichia fergusonii* (ICDC-ZG2016M34-3) at the level of 6pg per reaction was used  
179 as the templates. A series of temperatures (ranging from 60°C to 67°C, with 1°C intervals)  
180 was compared for amplifying efficiency of MCDA-LFB assay by employing 2% agarose  
181 gel electrophoresis. The result showed that 62°C and 63°C were the better candidates for  
182 this method (**Fig. 3**). Therefore, the reaction temperature of 63°C was performed for the  
183 subsequent MCDA-LFB experiments.

184 **Sensitivity and specificity of MCDA-LFB assay for *mcr-1*.** To acquire the  
185 detection limit of this assay, serial dilutions of *Escherichia fergusonii*

186 ICDC-ZG2016M34-3 plasmid DNA were used in *mcr-1*-MCDA-LFB assay. It indicated  
187 that the threshold was as little as 600 fg of plasmid DNA (Fig. 4). The same results were  
188 observed by using colorimetric indicator and agarose gel electrophoresis analysis.

189 The analytical specificity of the *mcr-1*-MCDA-LFB assay was assessed with  
190 genomic DNA extracted from 16 *mcr-1*-producing strains and 35 non-*mcr-1* isolates. As  
191 shown in Fig. 5, all products derived from the strains carrying *mcr-1* gene exhibited two  
192 red bands (TL and CL) in the LFB, but each sample from the *mcr-1*-negative organisms  
193 and blank control was only one red band. The results certified that the MCDA-LFB assay  
194 had a complete specificity for *mcr-1* detection.

195 **Optimization of the time for *mcr-1*-MCDA-LFB assay.** To evaluate the optimum  
196 time, four reaction times (10 min to 40 min at 10 min intervals) were tested for the  
197 *mcr-1*-MCDA-LFB assay during the amplification stage. The *mcr-1*-producing  
198 *Escherichia fergusonii* (ICDC-ZG2016M34-3) plasmid DNA, 600 fg/μl (the LOD of the  
199 method), did not gain the positive results until the reaction had operated for 30 min (Fig.  
200 6). Hence, the amplification time of 30 min at 63°C was considered as an optimal  
201 reaction condition for the current assay.

202 **Application of MCDA-LFB to *mcr-1*-spiked fecal samples.** The LOD for strains  
203 expressing *mcr-1* in fecal samples was determined to assess the practical application of  
204 the established assay. The detected threshold of *mcr-1*-positive bacteria was  
205 approximately  $4.5 \times 10^3$  CFU/mL ( $\sim 4.5$  CFU/reaction) in 0.2g faecal samples spiked with  
206 100 μl of dilutions of strains (Fig. 7). The results of other subjects including the lower

207 suspensions concentrations, negative control and blank control were negative.  
208 As the same to the aforementioned experiments, detection of the amplicons with three  
209 methods got an equal conclusion.

210

## 211 **Discussion**

212 Polymyxins (polymyxin B and colistin) have nearly become last-resort drugs for treating  
213 the severe infections caused by multidrug-resistant or pan-resistant *Enterobacteriaceae*  
214 (6). The defensive line will be destroyed by the emergence of *mcr-1*-positive strains  
215 resisting to colistin. Moreover, the *mcr-1* gene mediated by plasmids or transposons can  
216 transfer in different species freely. Thus, the isolates carrying *mcr-1* gene will  
217 undoubtedly become a major issue for public health. Under the circumstances, a  
218 convenient and fast technique for detection of *mcr-1* in various samples is of great  
219 importance. Here, an approach was reported to detect target gene by multiple cross  
220 displacement amplification united with lateral flow biosensor (MCDA-LFB). In the  
221 MCDA-LFB assay, the high specificity was guaranteed, as a set of 10 primers was  
222 employed for specially amplifying the target sequence. The specificity of  
223 *mcr-1*-MCDA-LFB was successfully confirmed with the genomic templates extracted  
224 from *mcr-1*-producing strains and non-*mcr-1* organisms, and the results were positive for  
225 all *mcr-1*-positive isolates, but negative for non-*mcr-1* isolates and blank control.  
226 Therefore, the diagnostic test based on MCDA-LFB for the detection of *mcr-1* in bacteria  
227 identifies target gene with high selectivity.

228 The MCDA products can be analyzed with LFB, colorimetric indicator and agarose  
229 gel electrophoresis, respectively. LFB, as a detection technique by observing the number  
230 of red lines on sensor bar, is more objective than colorimetric indicator, which reports the  
231 result through color change. Maybe the latter is in trouble when the concentration of  
232 target gene is very low (24). Likewise, LFB is more rapid and convenient than gel  
233 electrophoresis, which requires the use of an additional operation procedure and complex  
234 equipment. Hence, LFB will be a better candidate for the results' judge of MCDA  
235 products.

236 Besides specificity, the superb sensitivity is also very important for the newly  
237 established assay. The *mcr-I*-MCDA-LFB method sufficed to detect as little as 600 fg of  
238 *mcr-I*-positive plasmid DNA per microliter in pure culture and  $4.5 \times 10^3$  CFU/mL ( $\sim 4.5$   
239 CFU/reaction) in fecal samples spiked with 100  $\mu$ l of strains. This technique has the same  
240 sensitivity to *mcr-I*-LAMP described in previously report (25). Both isothermal  
241 amplification assays are 10 times more sensitive than conventional PCR (25). Although  
242 the Real-time PCR and MALDI-TOF MS-based method could also test the *mcr-I* gene  
243 with low limit of detection and less time, respectively (18, 26), they needed expensive  
244 apparatus and immaculately experimental condition that were not well equipped in  
245 resource-challenged fields, especially in the livestock industry where a large quantity of  
246 stains carrying *mcr* gene were identified (26).

247 The *mcr-I*-MCDA-LFB assay only required a constant reaction temperature at 63° C.  
248 The entire process of experiments, including sample processing (25 min), isothermal

249 amplification (30 min) and detection (2min), could be accomplished less than 60 min.  
250 Herein, this assay economizes the test time and device, and is suitable for timely  
251 identification on the spot particularly.

252 In conclusion, we devised a reliable MCDA-LFB assay for the detection of *mcr-1*  
253 with simplicity, rapidity, and low-cost facility. The LOD of this assay was only 600 fg per  
254 reaction with pure culture, and the specificity was 100% according to the trial results.  
255 From the above, the *mcr-1*-MCDA-LFB assay built in this study will greatly improve the  
256 detection efficiency for the monitor of target gene in practical application.

257

## 258 **Acknowledgements**

259 We acknowledge the financial supports (the research projects of clinical medicine in  
260 Wuhan, Grant Number:WG17Q02) from the Wuhan Municipal Health Commission,  
261 People's Republic of China. We would like to thank Prof. Juan Li and Jie Che(Chinese  
262 Center for Disease Control and Prevention) for providing partial isolates. We are also  
263 grateful to Dr. Yi Wang (Beijing Children's Hospital) for affording the technical  
264 guidance.

265

266

267

268

269

270 **Reference**

- 271 1. Nation RL, Li J. 2009. Colistin in the 21st century. *Curr Opin Infect Dis.* 22: 535-43.  
272 <http://dx.doi.org/10.1097/QCO.0b013e328332e672>.
- 273 2. Gelband H, Miller-Petrie MK, Pant S, Gandra S, Levinson J, Barter D, White A,  
274 Laxminarayan R. 2015. The state of the world's antibiotics 2015. *Wound Healing*  
275 *Southern Africa.* 8:30-34. <http://dx.doi.org/10.1097/10.3126/jcmc.v6i4.16721>.
- 276 3. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin resistance:  
277 acquired and intrinsic resistance in bacteria. *Front Microbiol.* 5:643.  
278 <http://dx.doi.org/10.3389/fmicb.2014.00643>.
- 279 4. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B,  
280 Huang X, Yu L, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Shen J. 2016.  
281 Emergence of plasmid-mediated colistin resistance mechanism *mcr-1* in animals and  
282 human beings in China: a microbiological and molecular biological study. *Lancet*  
283 *Infect Dis.* 16:161–8. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
- 284 5. Wang R, Dorp LV, Shaw LP, Bradley P, Wang Q, Wang X, Jin L, Zhang Q, Liu Y,  
285 Rieux A, Dorai-Schneiders T, Weinert LA, Iqbal Z, Didelot X, Wang H, Balloux F.  
286 2018. The global distribution and spread of the mobilized colistin resistance gene  
287 *mcr-1*. *Nat Commun.* 9: 1179. <https://doi.org/10.1038/s41467-018-03205-z>.
- 288 6. Wang Q, Sun J, Li J, Ding Y, Li XP, Lin JX, Hassan B, Feng Y. 2017. Expanding  
289 landscapes of the diversified *mcr-1*-bearing plasmid reservoirs. *Microbiome.* 5:70.  
290 <https://doi.org/10.1186/s40168-017-0288-0>.

- 291 7. Doumith M, Godbole G, Ashton P, Larkin L, Dallman T, Day M, Day  
292 M, Muller-Pebody B, Ellington MJ, de Pinna E, Johnson AP, Hopkins KL, Woodford  
293 N. 2016. Detection of the plasmid-mediated *mcr-1* gene conferring colistin resistance  
294 in human and food isolates of *Salmonella enterica* and *Escherichia coli* in England  
295 and Wales. J Antimicrob Chemother. 71:2300–5. <https://doi.org/10.1093/jac/dkw093>.
- 296 8. Li Z, Tan C, Lin J, Feng Y. 2016. Diversified variants of the *mcr-1*-carrying plasmid  
297 reservoir in the swine lung microbiota. Sci China Life Sci. 59:971-3. [https://doi.org/](https://doi.org/10.1007/s11427-016-5111-9)  
298 [10.1007/s11427-016-5111-9](https://doi.org/10.1007/s11427-016-5111-9).
- 299 9. Zeng KJ, Doi Y, Patil S, Huang X, Tian GB. 2016. Emergence of plasmid-mediated  
300 *mcr-1* gene in colistin-resistant *Enterobacter aerogenes* and *Enterobacter cloacae*.  
301 Antimicrob Agents Chemother. 60:3862-3. <https://doi.org/10.1128/AAC.00345-16>.
- 302 10. Stoesser N, Mathers AJ, Moore CE, Day NPJ, Crook DW. 2016. Colistin resistance  
303 gene *mcr-1* and pHNSHP45 plasmid in human isolates of *Escherichia coli* and  
304 *Klebsiella pneumoniae*. Lancet Infect Dis. 16:285-6. <https://doi.org/10.1016/S1473>  
305 [-3099\(16\)00010-4](https://doi.org/10.1016/S1473-3099(16)00010-4).
- 306 11. Sennati S, Di Pilato V, Riccobono E, Di Maggio T, Villagran AL, Pallecchi L,  
307 Bartoloni A, Rossolini GM, Giani T. 2017. *Citrobacter braakii* carrying  
308 plasmid-borne *mcr-1* colistin resistance gene from ready-to-eat food from a market in  
309 the Chaco region of Bolivia. J Antimicrob Chemother.72:2127-2129. [https://doi.org](https://doi.org/10.1093/jac/dkx078)  
310 [/10.1093/jac/dkx078](https://doi.org/10.1093/jac/dkx078).

- 311 12. Chen K, Chan EW, Xie M, Ye L, Dong N, Chen S. 2017. Widespread distribution of  
312 *mcr-I*-bearing bacteria in the ecosystem, 2015 to 2016. Euro Surveill.  
313 22:pii=17-00206. <https://doi.org/10.2807/1560-7917.ES.2017.22.39.17-00206>.
- 314 13. Yang RS, Feng Y, Lv XY, Duan JH, Chen J, Fang LX, Xia J, Liao XP, Sun J, Liu YH.  
315 2016. Emergence of NDM-5 and *MCR-I*-producing *Escherichia coli* clone ST648  
316 and ST156 from a single Muscovy duck (*Cairina moschata*). Antimicrob Agents  
317 Chemother. 60:6899–902. <https://doi.org/10.1128/AAC.01365-16>.
- 318 14. Sun J, Li XP, Yang RS, Fang LX, Huo W, Li SM, Jiang P, Liao XP, Liu YH. 2016.  
319 Complete nucleotide sequence of an IncI2 plasmid coharboring *bla*<sub>CTX-M-55</sub> and *mcr-I*.  
320 Antimicrob Agents Chemother. 60:5014–7. <https://doi.org/10.1128/AAC.00774-16>.
- 321 15. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, Hinkle M,  
322 Whitman T, Lesho E, Schaecher KE. 2016. *Escherichia coli* harboring *mcr-I* and  
323 *bla*<sub>CTX-M</sub> on a novel IncF plasmid: first report of *mcr-I* in the United States.  
324 Antimicrob Agents Chemother. 60:4420–1. <https://doi.org/10.1128/AAC.01103-16>.
- 325 16. Sun J, Fang LX, Wu Z, Deng H, Yang RS, Li XP, Li SM, Liao XP, Feng YJ, Liu YH.  
326 2017. Genetic analysis of the IncX4 plasmids: implications for a unique pattern in  
327 the *mcr-I* acquisition. Sci Rep. 7:424. <https://doi.org/10.1038/s41598-017-00095-x>.
- 328 17. Guo Q, Su J, McElheny CL, Stoesser N, Doi Y, Wang M. 2017. IncX2 and IncX1-X2  
329 hybrid plasmids coexisting in fosA6-producing *Escherichia coli*. Antimicrob Agents  
330 Chemother. 61: e00536-17. <https://doi.org/10.1128/AAC.00536-17>.



- 331 18. Bontron S, Poirel L, Nordmann P. 2016. Real-time PCR for detection of  
332 plasmid-mediated polymyxin resistance (*mcr-I*) from cultured bacteria and stools. J  
333 Antimicrob Chemother. 71: 2318-2320. <https://doi.org/10.1093/jac/dkw139>.
- 334 19. Niu L, Zhao F, Chen J, Nong J, Wang C, Wang J, Gao N, Zhu X, Wu L, Hu S. 2018.  
335 Isothermal amplification and rapid detection of *Klebsiella pneumoniae* based on the  
336 multiple cross displacement amplification (MCDA) and gold nanoparticle lateral  
337 flow biosensor (LFB). Plos one. 13: e0204332. [https://doi.org/10.1371/journal.pone.](https://doi.org/10.1371/journal.pone.0204332)  
338 [0204332](https://doi.org/10.1371/journal.pone.0204332).
- 339 20. Wang Y, Li H, Wang Y, Li H, Luo L, Xu J, Ye C. 2017. Development of multiple  
340 cross displacement amplification label-based gold nanoparticles lateral flow  
341 biosensor for detection of *Listeria monocytogenes*. Int J Nanomedicine. 12:473-486.  
342 [https://doi.org/ 10.2147/ IJN.S123625](https://doi.org/10.2147/IJN.S123625).
- 343 21. Wang Y, Yan W, Fu S, Hu S, Wang Y, Xu J, Ye C. 2018. Multiple cross displacement  
344 amplification coupled with nanoparticles-based lateral flow biosensor for detection  
345 of *Staphylococcus aureus* and identification of methicillin-resistant *S. aureus*. Front  
346 Microbiol. 9: 907. <https://doi.org/10.3389/fmicb.2018.00907>.
- 347 22. Wang Y, Li H, Wang Y, Xu H, Xu J, Ye C. 2018. Antarctic thermolabile uracil-DNA-  
348 glycosylase-supplemented multiple cross displacement amplification using a  
349 label-based nanoparticle lateral flow biosensor for the simultaneous detection of  
350 nucleic acid sequences and elimination of carryover contamination. Nano Research.  
351 11: 2632-2647. <https://doi.org/10.1007/s12274-017-1893-z>.

- 352 23. Wang Y, Li H, Li D, Li K, Wang Y, Xu J, Ye C. 2016. Multiple cross displacement  
353 amplification combined with gold nanoparticle-based lateral flow biosensor for  
354 detection of *Vibrio parahaemolyticus*. *Front Microbiol.* 7: 2047. [https://doi.org/](https://doi.org/10.3389/fmicb.2016.02047)  
355 [10.3389/fmicb.2016.02047](https://doi.org/10.3389/fmicb.2016.02047).
- 356 24. Wang Y, Li H, Wang Y, Zhang L, Zhang J, Xu J, Ye C. 2017. Nanoparticle-based  
357 lateral flow biosensor combined with multiple cross displacement amplification for  
358 rapid, visual and sensitive detection of *Vibrio cholerae*. *FEMS Microbiology Letters.*  
359 364. <https://doi.org/10.1093/femsle/fnx234>.
- 360 25. Zou D, Huang S, Lei H, Yang Z, Su Y, He X, Zhao Q, Wang Y, Liu W, Huang L.  
361 2017. Sensitive and rapid detection of the plasmid-encoded colistin-resistance gene  
362 *mcr-1* in *Enterobacteriaceae* isolates by loop-mediated isothermal amplification.  
363 *Front Microbiol.* 8:2356. <https://doi.org/10.3389/fmicb.2017.02356>.
- 364 26. Dortet L, Bonnin RA, Pennisi I, Gauthier L, Jousset AB, Dabos L, Furniss RCD,  
365 Mavridou DAI, Bogaerts P, Glupczynski Y, Potron A, Plesiat P, Beyrouthy R, Robin  
366 F, Bonnet R, Naas T, Filloux A, Larrouy-Maumus G. 2018. Rapid detection and  
367 discrimination of chromosome- and MCR-plasmid-mediated resistance to  
368 polymyxins by MALDI-TOF MS in *Escherichia coli*: the MALDIxin test. *J*  
369 *Antimicrob Chemother.* 73:3359-67. <https://doi.org/10.1093/jac/dky330>.

370 **TABLE 1. Strains used in this study.**

Genotype <sup>a</sup>	Bacteria species	The source of strains <sup>b</sup>	No. of isolates
<i>mcr-1</i>	<i>Escherichia fergusonii</i>	ICDC (ZG2016M34-3)	1
	<i>Escherichia fergusonii</i>	ICDC	3
	<i>Escherichia fergusonii</i>	WHCDC	1
	<i>Escherichia coli</i>	ICDC	8
	<i>Escherichia coli</i>	WHCDC	2
	<i>Salmonella enteritidis</i>	ICDC	1
KPC-2	<i>Klebsiella pneumoniae</i>	WHCDC	10
	<i>Pseudomonas aeruginosa</i>	WHCDC	1
NDM-1	<i>Escherichia coli</i>	WHCDC	4
	<i>Enterobacter cloacae</i>	WHCDC	2
	<i>Klebsiella pneumoniae</i>	WHCDC	4
NDM-5	<i>Escherichia coli</i>	WHCDC	2
IMP-4	<i>Escherichia coli</i>	WHCDC	2
NO	<i>Acinetobacter baumannii</i>	WHCDC	3
	<i>Pseudomonas aeruginosa</i>	WHCDC	3
	<i>Serratia marcescens</i>	WHCDC	2
	<i>Escherichia coli</i>	WHCDC	2

371 <sup>a</sup> NO, the stains did not carry above genes. <sup>b</sup> ICDC, National Institute for Communicable Disease

372 Control and Prevention, Chinese Center for Disease Control and Prevention. WHCDC, Wuhan

373 Centers for Disease Prevention & Control.

374

375

376

377

378

379

380 **TABLE 2. Primers of the MCDA assay to identify the *mcr-1* gene.**

Primers <sup>a</sup>	Sequences and modifications (5'-3')	Length <sup>b</sup>
F1	GCTGACGATCGCTGTGCG	17 nt
F2	CGCTGCGTTTAATAGATCCT	20 nt
CP1	AACACAGGCTTTAGCACATAGCGATCTTTGGCGCGATGCTACT	43 mer
CP2	TGACACTTATGGCACGGTCTATGCTTGGTCGGTCTGTAGG	40 mer
C1*	FITC-AACACAGGCTTTAGCACATAGCGAT	25 nt
C2	TGACACTTATGGCACGGTCTAT	22 nt
D1*	biotin-GATGATAACAGCGTGGTGAT	20 nt
D2	GATACGACCATGCTCCAA	18 nt
R1	GCCCATGATTAATAGCAA	18 nt
R2	CGGTGACCAGTTATTTTAC	19 nt

381 <sup>a</sup> C1\*, 5' end of C1 was labeled with FITC; D1\*, 5' end of D1 was labeled with biotin. <sup>b</sup> nt meant  
382 the nucleotide; mer referred to monomeric.

383

384

385

386

387

388

389

390

391

```
CTCGGCTTTGTGCTGACGATCGCTGTCGTGCTCTTTGGCGCG
      F1                                P1
ATGCTACTGATCACCACGCTGTTATCATCGTATCGCTATGTGCT
      D1                                C1
AAAGCCTGTGTTGATTGCTATTAATCATGGGC CGGGTGACC
      R1                                R2
AGTTATTTTAC TGACACTTATGGCACGGTCTAJ GATACGACCAT
      C2                                D2
GCTCCA AATGCCTACAGACCGACCAAGCCGAGACCAAGGA
      P2
      F2
TCTATTAACGCAGCGTTTAT
```


392

393 **FIG 1.** The location of the five primers pairs on the partial *mcr-1* gene sequence. Different pairs of  
394 primers were represented by various of colors. The arrowed lines showed the amplification direction  
395 of primers.

396


397

398




399

400 **FIG 2.** Confirmation of the *mcr-1*-MCDA-LFB assay. There were three detection methods to identify  
401 MCDA products: (a) colorimetric indicators, (b) agarose gel electrophoresis, (c) LFB. Four samples  
402 were tested: 1. *mcr-1*-positive strain of *Escherichia fergusonii* (ICDC-ZG2016M34-3); 2.  
403 NDM-1-positive *Escherichia coli* (WHCDC-WH67); 3. KPC-2-producing *Klebsiella pneumoniae*  
404 (WHCDC-WH108); 4. distilled water. Only the amplification with *Escherichia fergusonii* (ICDC-  
405 ZG2016M34-3) showed the positive.




406

407 **FIG 3.** Optimal reaction temperature for *mcr-I*-MCDA assay was determined by using agarose gel  
408 electrophoresis. The plasmid DNA of *Escherichia fergusonii* (ICDC-ZG2016M34-3) (6pg) was  
409 amplified in different temperatures. Lane 1–8 represented the ampication temperature in the range  
410 from 60°C to 67°C (1°C intervals); lane 9, negative control (6 pg of *Escherichia coli* WHCDC-WH67  
411 genomic DNA); lane 10, blank control (DW).



412

413 **FIG 4.** Sensitivity of the *mcr-I*-MCDA assay using serially diluted plasmid DNA with *Escherichia*  
414 *fergusonii* ICDC-ZG2016M34-3. Three detection techniques, including colorimetric indicators (A),  
415 gel electrophoresis (B) and LFB (C), were applied for testing MCDA products. Tubes (A)/lanes  
416 (B)/biosensors(C) 1-8 represented the plasmid DNA levels of 6 ng, 60 pg, 600 fg, 60 fg and 6 fg per  
417 reaction, negative control ( NDM-1-positive *Escherichia coli* WHCDC-WH67 genomic DNA, 6 pg  
418 per reaction), negative control ( KPC-2-producing *Klebsiella pneumoniae* WHCDC-WH108 genomic  
419 DNA, 6 pg per reaction) and blank control (DW).




420

421 **FIG 5.** Specificity of the *mcr-I*-MCDA-LFB assay. Biosensor 1, *mcr-I*-positive *Escherichia*  
422 *fergusonii* ICDC-ZG2016M34-3. Biosensor 2, *mcr-I*-positive *Escherichia fergusonii* from ICDC.  
423 Biosensor 3, *mcr-I*-positive *Escherichia fergusonii* from WHCDC. Biosensor 4, *mcr-I*-producing  
424 *Escherichia coli* from ICDC. Biosensor 5, *mcr-I*-producing *Escherichia coli* from WHCDC.  
425 Biosensor 6, *mcr-I*-producing *Salmonella enteritidis* from ICDC. Biosensors 7-17, KPC-2-positive  
426 *Klebsiella pneumoniae*, KPC-2-positive *Pseudomonas aeruginosa*, NDM-1-positive *Escherichia coli*,  
427 NDM-1-positive *Enterobacter cloacae*, NDM-1-positive *Klebsiella pneumoniae*, NDM-5-positive  
428 *Escherichia coli*, IMP-4-positive *Escherichia coli*, *Acinetobacter baumannii* carrying  
429 non-*mcr-I*/non-carbapenemase gene, *Pseudomonas aeruginosa* carrying non-*mcr-I*/non carbapenemase  
430 gene, *mcr-I*/carbapenemase-negative *Serratia marcescens*, *mcr-I*/carbapenemase-negative  
431 *Escherichia coli*, all of the stains derived from WHCDC. Biosensor 18, blank control (DW).

432

433

434



435

436 **FIG 6.** The optimal reaction time for *mcr-I*-MCDA-LFB assay. Four different amplification

437 times ,covering 10min (A), 20min (B) , 30min (C) and 40min (D), were compared at 63°C. Biosensors


438 1-8 represented the plasmid DNA levels of 60 pg, 6 pg, 600 fg, 60 fg and 6 fg of *Escherichia*

439 *fergusonii* ICDC-ZG2016M34-3, negative control (6 pg of NDM-1-positive *Escherichia coli*

440 WHCDC-WH67 genomic DNA), negative control (6 pg of KPC-2-producing *Klebsiella pneumoniae*

441 WHCDC-WH108 genomic DNA) and blank control (DW).

442



443

444 **FIG 7.** Sensitivity of *mcr-I*-MCDA-LFB assay in spiked feces samples. Three measurement

445 techniques, including colorimetric indicators (A), gel electrophoresis (B) and LFB (C), were applied

446 for testing MCDA products. Tubes (A)/lanes (B)/biosensors(C) 1-8 represented the DNA levels of  $4.5 \times 10^3$

447  $\times 10^3$  CFU,  $4.5 \times 10^2$  CFU,  $4.5 \times 10^1$  CFU,  $4.5 \times 10^0$  CFU,  $4.5 \times 10^{-1}$  CFU and  $4.5 \times 10^{-2}$  CFU per

448 reaction, negative control (non-spiked feces sample) and blank control (DW).

449